HONG KONG – Samsung Bioepis Co. Ltd., the biopharmaceutical arm of the South Korean conglomerate, is looking to take high-quality biosimilars global in just two years. For the company, which is expanding its footprint in that competitive space, it all comes down to 2016.
HONG KONG – This year has been a good one for biopharma companies in China, many of which are combining a growing market with stronger R&D pipelines, some government support and more tightly controlled expenses and are turning out some positive results.
SHANGHAI – Shanghai is the final leg of Johnson & Johnson's world tour of innovation hot spots – having just cut the ribbon on its fourth J&J Innovation Centre after doing so in London, Boston and California. The Asia Pacific Innovation Center promises to open up J&J resources to the region's best minds in pharmaceuticals, medical devices and health care products. Their aim is clear, to close the gaps in the life sciences ecosystem to accelerate innovation.
SHANGHAI – Biotech acquisitions are increasingly becoming a part of the Chinese outbound investment story. This time around, up and comer Betta Pharmacuetical Co., of Hangzhou, Zhejiang, has made a $20 million equity investment in Xcovery Inc., of West Palm Beach, Fla.
SUZHOU, China – The China growth story continues to buoy the life science industry, even in the face of challenging headwinds of change. That was the message from PwC experts who extensively surveyed executives and innovators across device, service, venture capital and pharma, many of whom were in the room for the recent collegial ChinaBio Leadership Retreat in Changshu.
SEOUL, South Korea – South Korean companies focused on research and development of stem cell therapy products are working hard to put the country back into a position of global leadership, even after setbacks in the last decade that held back research for years.
From a purely scientific standpoint, the news about the Ebola outbreak has been encouraging. New genomic technologies enable unprecedented surveillance of the virus. There are drugs and vaccines in clinical trials. And in response to the urgency of the crisis, both drugmakers and regulatory agencies are making efforts to expedite the process of getting weapons against Ebola through the regulatory process and into the field, where they are needed.
HONG KONG – Chinese researchers have demonstrated that grafted neural stem cells directly release dopamine into the damaged striata of rat brains in vivo and partially rescued a model of Parkinson's disease (PD), providing proof of concept for the feasibility of that technique for treating PD in humans.
SEOUL, South Korea – Vaccine makers in Asian emerging markets are stepping up their development efforts, while researchers are increasingly helping developing countries troubled by neglected diseases by partnering with domestic manufactures, often in neighboring countries.
Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its subsidiary, Twi Biotechnology Inc., gained FDA orphan drug status for AC-201, a drug it is developing for rare genetic connective tissue disorder epidermolysis bullosa, a pediatric disorder that leaves children with fragile skin that blisters and tears from friction or trauma.
RSS